Akso Health Group Received Nasdaq Notification Letter Regarding Stockholders' Equity Deficiency
Akso Health Group (NASDAQ: AHG) announced it received a notification from Nasdaq on February 28, 2023, indicating it is non-compliant with the minimum stockholders' equity requirement of $10 million. As of September 30, 2022, Akso reported approximately $9.9 million in stockholders' equity. While this notification does not immediately affect its listing, Akso has until April 14, 2023, to propose a compliance plan. If accepted, Nasdaq may grant an extension of up to 180 days, extending the compliance deadline to August 27, 2023.
Akso continues to operate within the social e-commerce and healthcare equipment sectors, previously known as Xiaobai Maimai.
- The notification does not have an immediate effect on the listing of Akso Health's ADSs on Nasdaq.
- The company is working with advisors to develop a compliance plan which could extend its compliance deadline.
- Akso's reported stockholders' equity of $9.9 million is below the Nasdaq minimum requirement of $10 million.
- Failure to regain compliance may threaten its listing on Nasdaq.
BEIJING, March 06, 2023 (GLOBE NEWSWIRE) -- Akso Health Group (NASDAQ: AHG) ("Akso Health" the "Company" or “we”), today announced that on February 28, 2023, the Company received a notification letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is no longer in compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Global Market set forth in Nasdaq Listing Rule 5450(b)(1)(A) (the "Nasdaq Listing Rules"). The Nasdaq Listing Rules requires listed companies to maintain stockholders' equity of at least
The notification received has no immediate effect on the listing of the Company's ADSs on Nasdaq. Nasdaq has provided the Company with 45 calendar days, or until April 14, 2023, to submit a plan to regain compliance with the minimum stockholders' equity standard. The Company will be working with its advisors to submit a plan of compliance, that if accepted by Nasdaq, can grant an extension of up to 180 calendar days from the date of the notification letter, or until August 27, 2023.
The Company, by filing this press release, discloses its receipt of the notification from Nasdaq in accordance with Nasdaq Listing Rule 5810(b).
About Akso Health Group
Akso Health Group (NASDAQ: AHG), formerly known as Xiaobai Maimai Inc., operates a social e-commerce platform in China that collaborates with other domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products. Since the end of 2021, the Company also started exploring the healthcare equipment and product trading and related healthcare services business.
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "potential," "continue," "ongoing," "targets," "guidance" and similar statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC"), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Any statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements that involve factors, risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such factors and risks include, but not limited to the following: risks related to our ability to obtain equipment, technology, license and talents at satisfactory terms to start the planned business, if at all; risks regarding the effect of the COVID-19 pandemic on the Company and the Company's position in a post-COVID-19 environment; risks related to the Company's ability to adapt and make the necessary adjustments to compete and operate effectively; risks related to decisions or changes in governmental or private insurers' reimbursement levels for our radiotherapy services or our ability to obtain reimbursement for our radiotherapy services; risks related to increased competition and the development of new competing services; the risk that we may be unable to develop or achieve commercial success for radiotherapy services in a timely manner, or at all; risks related to regulatory requirements or enforcement in the United States and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to successfully integrate and derive benefits from any technologies that we license or acquire; risks related to our projections about our business, results of operations and financial condition; and risks related to the potential market opportunity for our products and services. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the SEC. All information provided in this announcement is current as of the date of this announcement, and the Company does not undertake any obligation to update such information, except as required under applicable law.
For more information, please visit http://www.ahgtop.com/en/index.html
For investor inquiries, please contact:
The Company
Investor Relations
Mr. Simon He
Email: ir@ahgtop.com
FAQ
What happened to Akso Health Group on February 28, 2023?
What is the stockholders' equity reported by Akso Health Group?
What is the compliance deadline for Akso Health Group?
What are the potential consequences if Akso fails to comply?
What extension can Akso Health Group receive from Nasdaq?
